A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
作者信息
Kim Miso, Lee Jeong-Ok, Koh Jiwon, Kim Tae Min, Lee Ji Yun, Jeon Yoon Kyung, Keam Bhumsuk, Kim Dong-Wan, Lee Jong Seok, Heo Dae Seog
机构信息
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam.
出版信息
Haematologica. 2021 Aug 1;106(8):2277-2280. doi: 10.3324/haematol.2021.278301.
Abstract
摘要
Zotero 插件